COI disclosure: I have a conflict of interest as the founder of NextPep, a peptide research and comparison platform. I'm filing this Edit Request rather than editing directly. Full disclosure at User:Karl Vorwerg.
I made a related direct edit to this article on 2026-05-12, which was reverted by another editor following the COI notice SmartSE posted on my Talk page. I accept that revert as appropriate given my COI, and I'm refiling the substance of that change here through the proper channel so an uninvolved editor can evaluate the content on its merits.
Proposed addition
In the Doping in sports section, the first paragraph currently reads:
Thymosin beta-4 is considered a performance-enhancing substance and is banned in sports by the World Anti-Doping Agency due to its effect of aiding soft tissue recovery and enabling higher training loads.[1] It was central to two controversies in Australia in the 2010s...
I propose inserting one sentence between the existing first and second sentence:
...higher training loads.[1] The synthetic peptide marketed and detected as "TB-500" under WADA's monitoring program is a seven-amino-acid fragment (LKKTETQ; residues 17–23 of full Tβ4; molecular weight ~889 Da) corresponding to the minimal actin-binding motif of the parent 43-residue protein, although the term is commonly used interchangeably with full-length thymosin beta-4 in the research-peptide and doping-control literature.[2][3] It was central to two controversies...
Why this improves the article
The article already cites Ho et al. 2012, whose title is literally "Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma..." — the fragment distinction is in the citation title but not in the body text. A reader who doesn't click the reference doesn't learn that "TB-500" and "thymosin beta-4" refer to different molecules. The Doping section uses both terms interchangeably, which leaves the basic factual distinction inaccessible to a general reader.
Van Troys et al. 1996 (PMID 8670856) established that residues 17–23 of Tβ4 constitute the minimal actin-binding motif, which is exactly the sequence that synthetic "TB-500" replicates.
Sources
Both already available — no new sources are strictly required for the proposed sentence:
- Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD (November 2012). "Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry". Journal of Chromatography A. 1265: 57–69. doi:10.1016/j.chroma.2012.09.043. PMID 23084823. (already cited in the article as the third reference in the Doping in sports section)
- Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C (1996). "The actin binding site of thymosin beta 4, mapped by mutational analysis". The EMBO Journal. 15 (2): 201–210. doi:10.1002/j.1460-2075.1996.tb00350.x. PMID 8670856.
Optional supplementary source
A secondary explainer synthesising the fragment-vs-protein distinction for general readers exists at https://nextpep.app/blog/tb-500-vs-thymosin-beta-4 . I authored this; I'm disclosing the COI here and noting that the proposed clarification stands on the two primary sources above without it. Whether to include the secondary source as an additional citation is entirely at the reviewing editor's discretion — either outcome is acceptable to me, and I will not contest the decision.
Thank you for the review.
Karl Vorwerg (talk) 12:37, 12 May 2026 (UTC)
Not done for now: @Karl Vorwerg I admit skepticism that the reader actually needs to know about TB-500, given that it isn't currently mentioned in the article except as a see also. I also think that the conclusion that TB-500 is confused for Thymosin beta-4 is WP:OR. I'm open to discussing this with you, but I'm closing the request so that its out of the queue. CaptainEek Edits Ho Cap'n!⚓ 04:53, 15 August 2026 (UTC)
